Brokerages Expect Express Scripts Holding (ESRX) Will Post Quarterly Sales of $25.12 Billion

Analysts expect that Express Scripts Holding (NASDAQ:ESRX) will post $25.12 billion in sales for the current quarter, according to Zacks Investment Research. Twelve analysts have provided estimates for Express Scripts’ earnings, with the highest sales estimate coming in at $25.54 billion and the lowest estimate coming in at $24.54 billion. Express Scripts reported sales of $24.86 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 1%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 27th.

On average, analysts expect that Express Scripts will report full-year sales of $25.12 billion for the current financial year, with estimates ranging from $99.22 billion to $100.51 billion. For the next fiscal year, analysts expect that the company will post sales of $100.60 billion per share, with estimates ranging from $99.93 billion to $101.33 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Express Scripts.

Express Scripts (NASDAQ:ESRX) last issued its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The business had revenue of $24.68 billion during the quarter, compared to the consensus estimate of $25.68 billion. During the same period last year, the company earned $1.74 EPS. The company’s revenue for the quarter was down 2.9% on a year-over-year basis.

A number of brokerages recently issued reports on ESRX. SunTrust Banks reissued a “buy” rating and set a $95.00 price objective on shares of Express Scripts in a research report on Friday, January 12th. Robert W. Baird reissued a “buy” rating and set a $92.00 price objective (up from $81.00) on shares of Express Scripts in a research report on Tuesday, January 9th. Evercore ISI began coverage on Express Scripts in a research report on Thursday, January 4th. They set an “in-line” rating and a $78.00 price objective for the company. BidaskClub raised Express Scripts from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Express Scripts in a research report on Thursday, December 21st. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $77.09.

Shares of Express Scripts (NASDAQ:ESRX) opened at $80.22 on Friday. Express Scripts has a 52 week low of $55.80 and a 52 week high of $81.75. The stock has a market capitalization of $45,434.44, a price-to-earnings ratio of 11.73, a price-to-earnings-growth ratio of 0.89 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86.

Express Scripts declared that its board has authorized a stock repurchase plan on Monday, December 18th that permits the company to repurchase 45,000,000 shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

In other Express Scripts news, VP Glen D. Stettin sold 3,449 shares of Express Scripts stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $81.00, for a total value of $279,369.00. Following the completion of the transaction, the vice president now directly owns 33,715 shares of the company’s stock, valued at approximately $2,730,915. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Timothy C. Wentworth bought 8,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was purchased at an average cost of $61.13 per share, with a total value of $489,040.00. Following the completion of the transaction, the chief executive officer now owns 98,628 shares in the company, valued at $6,029,129.64. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 17,644 shares of company stock valued at $1,289,609. 0.68% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sandy Spring Bank grew its position in Express Scripts by 0.6% in the 2nd quarter. Sandy Spring Bank now owns 6,464 shares of the company’s stock valued at $413,000 after acquiring an additional 37 shares in the last quarter. Stonebridge Capital Advisors LLC grew its position in Express Scripts by 0.4% in the 2nd quarter. Stonebridge Capital Advisors LLC now owns 24,059 shares of the company’s stock valued at $1,536,000 after acquiring an additional 100 shares in the last quarter. National Asset Management Inc. grew its position in Express Scripts by 1.5% in the 2nd quarter. National Asset Management Inc. now owns 7,939 shares of the company’s stock valued at $510,000 after acquiring an additional 115 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its stake in shares of Express Scripts by 3.2% in the 2nd quarter. San Francisco Sentry Investment Group CA now owns 4,487 shares of the company’s stock valued at $286,000 after buying an additional 138 shares during the period. Finally, Ironwood Investment Counsel LLC boosted its stake in shares of Express Scripts by 2.7% in the 2nd quarter. Ironwood Investment Counsel LLC now owns 5,327 shares of the company’s stock valued at $340,000 after buying an additional 140 shares during the period. 88.21% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/01/21/brokerages-expect-express-scripts-holding-esrx-will-post-quarterly-sales-of-25-12-billion.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get a free copy of the Zacks research report on Express Scripts (ESRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit